MAL2: A Potential Drug Target Or Biomarker (G114569)

Target Name: MAL2

NCBI ID: G114569

MAL2

MAL2: A Potential Drug Target Or Biomarker

MAL2 (MAL2-HUMAN), a protein that is expressed in various tissues of the human body, has been identified as a potential drug target or biomarker in various diseases, including cancer, neurodegenerative diseases, and autoimmune disorders. Its unique structure and function have made it an attractive target for researchers to study, and its potential as a drug or biomarker has led to a growing interest in the development of new treatments.

MAL2 is a protein that is expressed in various tissues of the human body, including the brain, heart, liver, and muscle. It is a member of the integrin receptor family, which is a large family of transmembrane proteins that play a crucial role in cell-cell adhesion and signaling. MAL2 is a 21-kDa protein that consists of an extracellular domain, a transmembrane domain, and an intracellular domain.

One of the key features of MAL2 is its transmembrane domain. This domain is responsible for the protein's ability to interact with various signaling molecules, including tyrosine and chemokines. MAL2's transmembrane domain has been shown to play a role in several signaling pathways, including the regulation of cell adhesion, migration, and survival.

MAL2's unique structure and function have made it an attractive target for researchers to study. Its transmembrane domain and various post-translational modifications, such as phosphorylation and ubiquitination, have been shown to play important roles in the regulation of cellular processes. Additionally, its expression pattern in various tissues and its ability to interact with signaling molecules have led researchers to believe that it may be a potential drug target or biomarker.

MAL2 has been shown to be involved in several diseases, including cancer, neurodegenerative diseases, and autoimmune disorders. For example, MAL2 has been shown to be involved in the regulation of cancer cell growth and metastasis. Several studies have shown that MAL2 is highly expressed in various types of cancer, including breast, ovarian, and colorectal cancer. Additionally, MAL2 has been shown to play a role in the regulation of neurodegenerative diseases, such as Alzheimer's disease and Parkinson's disease.

In addition to its potential role in disease, MAL2 has also been shown to be a potential drug target. Its transmembrane domain and various post-translational modifications make it an attractive target for small molecules and antibodies that can modulate its function. Several studies have shown that MAL2 can be targeted by small molecules, including inhibitors of tyrosine kinase and inhibitors of protein kinase. Additionally, MAL2 has been shown to be a potential biomarker for several diseases, including cancer and neurodegenerative diseases.

In conclusion, MAL2 is a protein that has been identified as a potential drug target or biomarker in several diseases. Its unique structure and function, as well as its expression in various tissues and its ability to interact with signaling molecules, make it an attractive target for researchers to study. Further research is needed to fully understand its role in disease and its potential as a drug or biomarker.

Protein Name: Mal, T Cell Differentiation Protein 2

Functions: Member of the machinery of polarized transport. Required for the indirect transcytotic route at the step of the egress of the transcytosing cargo from perinuclear endosomes in order for it to travel to the apical surface via a raft-dependent pathway

The "MAL2 Target / Biomarker Review Report" is a customizable review of hundreds up to thousends of related scientific research literature by AI technology, covering specific information about MAL2 comprehensively, including but not limited to:
•   general information;
•   protein structure and compound binding;
•   protein biological mechanisms;
•   its importance;
•   the target screening and validation;
•   expression level;
•   disease relevance;
•   drug resistance;
•   related combination drugs;
•   pharmacochemistry experiments;
•   related patent analysis;
•   advantages and risks of development, etc.
The report is helpful for project application, drug molecule design, research progress updates, publication of research papers, patent applications, etc. If you are interested to get a full version of this report, please feel free to contact us at BD@silexon.ai

More Common Targets